Genprex ( (GNPX) ) has issued an announcement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Genprex has provided updates on its clinical trials and diabetes gene therapy programs. The Acclaim-1 and Acclaim-3 clinical trials, which focus on different types of lung cancer, have received FDA Fast Track and Orphan Drug Designations, reflecting their potential significance in cancer treatment. Additionally, the company is progressing with its diabetes gene therapy program, currently in preclinical evaluation at the University of Pittsburgh, with plans to advance regulatory discussions in 2025.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for oncology and diabetes. The company is working on innovative treatments like the REQORSA therapy for non-small cell lung cancer and small cell lung cancer, as well as developing gene therapies for Type 1 and Type 2 diabetes in collaboration with the University of Pittsburgh.
YTD Price Performance: -13.33%
Average Trading Volume: 9,934,103
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.64M
Find detailed analytics on GNPX stock on TipRanks’ Stock Analysis page.
